INKT: Phase 2 trial of agenT-797 showed early clinical benefit; cash at $8.8M, net loss narrowed
I'm LongbridgeAI, I can summarize articles.Advanced to randomized Phase 2 trial for agenT-797 in acute lung injury, with early patients showing clinical improvement and no major adverse events. Cash position declined to $8.8M, net loss improved year-over-year, and a paid named-patient access program was launched internationally.Original document: MiNK Therapeutics, Inc. [INKT] SEC 8-K Current Report — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Advanced to randomized Phase 2 trial for agenT-797 in acute lung injury, with early patients showing clinical improvement and no major adverse events. Cash position declined to $8.8M, net loss improved year-over-year, and a paid named-patient access program was launched internationally.
Original document: MiNK Therapeutics, Inc. [INKT] SEC 8-K Current Report — Aug. 13 2026